About Transcobalamin-2
Transcobalamin-2 (TCN2) is a protein
from Homo sapiens identified by UniProt accession
P20062, 427 residues long.
MolForge cross-references it against 0 known binders and
151 disease associations.
Target properties
| Protein name | Transcobalamin-2 |
|---|
| UniProt accession | P20062 |
|---|
| Gene | TCN2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 427 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (151)
Diseases linked to this target (Open Targets).
- transcobalamin II deficiency · score 0.75
- Transcobalamin deficiency · score 0.66
- Pancytopenia · score 0.63
- agammaglobulinemia · score 0.54
- Failure to thrive · score 0.51
- Thrombocytopenia · score 0.50
- neutropenia · score 0.50
- Intellectual disability · score 0.46
- Agranulocytosis · score 0.46
- severe combined immunodeficiency · score 0.46
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P20062-F1 | alphafold | PREDICTED | 91.52 | — |
Amino-acid sequence (427 residues)
MRHLGAFLFL LGVLGALTEM CEIPEMDSHL VEKLGQHLLP WMDRLSLEHL NPSIYVGLRL SSLQAGTKED LYLHSLKLGY QQCLLGSAFS EDDGDCQGKP SMGQLALYLL ALRANCEFVR GHKGDRLVSQ LKWFLEDEKR AIGHDHKGHP HTSYYQYGLG ILALCLHQKR VHDSVVDKLL YAVEPFHQGH HSVDTAAMAG LAFTCLKRSN FNPGRRQRIT MAIRTVREEI LKAQTPEGHF GNVYSTPLAL QFLMTSPMRG AELGTACLKA RVALLASLQD GAFQNALMIS QLLPVLNHKT YIDLIFPDCL APRVMLEPAA ETIPQTQEII SVTLQVLSLL PPYRQSISVL AGSTVEDVLK KAHELGGFTY ETQASLSGPY LTSVMGKAAG EREFWQLLRD PNTPLLQGIA DYRPKDGETI ELRLVSW
Explore Transcobalamin-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets